Inventiva (IVA) has released an update.
Inventiva has released promising results from its Phase 2 LEGEND study, showing that the combination of lanifibranor and empagliflozin significantly improves HbA1c levels in patients with metabolic dysfunction-associated steatohepatitis (MASH) and Type 2 Diabetes. The study demonstrated that 50% of patients achieved HbA1c levels below 6.5% after 24 weeks, with notable improvements in liver function and cardiometabolic health markers. These findings suggest potential benefits for the combination therapy in addressing both liver and metabolic health in affected patients.
For further insights into IVA stock, check out TipRanks’ Stock Analysis page.
